STAT

Purdue Pharma seeks to minimize its role in opioid crisis as it urges dismissal of Massachusetts suit

A lawyer for OxyContin maker Purdue Pharma said it was a "serious misconception" that the company created the opioid epidemic.

BOSTON — OxyContin maker Purdue Pharma on Friday sought to minimize its role both in the opioid addiction crisis and as a player in the painkiller industry as it asked a Massachusetts judge to dismiss a lawsuit from the state.

The state alleges the company’s deceptive marketing of its drugs spawned the opioid epidemic in Massachusetts, but a lawyer for the company pushed back against that claim.

“The notion that Purdue has created this epidemic is a serious misperception,” attorney Timothy Blank argued for Purdue.

The arguments in Suffolk County Superior Court are the latest turn in Massachusetts Attorney General Maura Healey’s lawsuit against Purdue, members of the Sackler family, who control the company, and executives and board members.

Judge Janet Sanders did not

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks